GlassScriptPhysician profile
Caroline Chance
NPI 1730969429
$3,430.35
in general payments reported to CMS, 2019-2025
25 companies · $2,015 in 2025
The $2,015 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $78.55 · 2024: $1,336 · 2025: $2,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,430.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $491.32 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $406.27 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $326.27 | 2024-2025 | Rexulti |
| Abbvie INC. | $303.75 | 2024-2025 | |
| Lilly USA, LLC | $269.94 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.84 | 2024-2025 | Jardiance |
| Axsome Therapeutics, INC. | $231.97 | 2024-2025 | Sunosi, Auvelity, Symbravo |
| Teva Pharmaceuticals USA, INC. | $178.09 | 2023-2025 | Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $160.36 | 2024-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $158.31 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.26 | 2024-2025 | Xifaxan |
| Corium, LLC | $96.83 | 2025 | Azstarys |
| Sumitomo Pharma America, INC. | $93.53 | 2024-2025 | Gemtesa |
| Glaxosmithkline, LLC. | $89.26 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Dexcom, INC. | $38.74 | 2024 | Dexcom G6 Transmitter |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $31.30 | 2025 | |
| Pfizer INC. | $29.78 | 2024-2025 | |
| Seqirus USA INC | $23.98 | 2025 | Flucelvax |
| Takeda Pharmaceuticals U.S.A., INC. | $20.80 | 2023 | Trintellix |
| Paratek Pharmaceuticals, INC. | $18.59 | 2024 | Nuzyra |
| Antares Pharma, INC. | $18.35 | 2025 | Xyosted |
| Halozyme INC | $16.53 | 2023 | |
| Tris Pharma INC | $16.07 | 2025 | Onyda Xr |
| Astellas Pharma US INC | $15.23 | 2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $14.98 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Chance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.